Please select the option that best describes you:
What are your thoughts on the use of icosapent ethyl in clinical practice for patients with hypertriglyceridemia, and its safety profile such as increased risk of atrial fibrillation?
Secondary composite end points included sudden cardiac death, fatal and nonfatal myocardial infarction, unstable angina requiring emergency hospitalization in RESPECT-EPA (Miyauchi, et al., PMID 38873793).